NEW DELHI: On the second day of President Donald Trump‘s first visit to India, New Delhi and Washington signed two bilateral pacts for strengthening cooperation in the mental and emotional wellbeing and generic medicine regimes.
The first agreement is expected to enable India learn from the US’s research and experience in treating mental health issues that have emerged as a concern here. According to a Lancet report, the burden of mental health disorders has been increasing rapidly in India from 3% in 1990 to 6% in 2013. Most cases are not reported as 80% of people with any form of mental disorder do not seek treatment.
The memorandum of understanding (MoU) between the two countries stresses use of Indian traditional therapies and medicines to address mental health issues as well as facilitate greater access to such drugs and therapies to the large US market.
The second pact is to help increase access to generic drugs in the US, which has been among the largest markets in the world for generic drugs while India is a large producer of such medicines. This MoU will allow India to strengthen its food and drug protocols and improve access for generics in the US market as well benefit Indian consumers by ensuring higher standards of generic drug standard compliance.
The pacts came after Prime Minister Narendra Modi said the two countries have decided to take their ties to a comprehensive global partnership level.


Source link